DELRAY BEACH, Fla., May 26, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that Chairman and CEO William J. Caragol will present at the 2016 Marcum MicroCap Conference on June 1, 2016 at 2:30 pm ET, at the Grand Hyatt in New York City.
Caragol will provide an update on PositiveID’s molecular diagnostics business including its Firefly Dx real-time pathogen detection system; E-N-G Mobile Systems, its mobile labs business; and Thermomedics, its medical device business, which markets the Caregiver ® FDA-cleared, non-contact thermometer.
PositiveID’s Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results from a sample in less than 30 minutes, compared to hours or even days for a lab device, using real-time PCR (polymerase chain reaction) chemistry. The Company announced yesterday that the Firefly Dx PCR breadboard prototype pathogen detection system successfully detected the Zika virus. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
About the Marcum MicroCap Conference The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. The Marcum MicroCap Conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year.
About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com , or connect with PositiveID on Twitter , Facebook or LinkedIn .
Statements about PositiveID's future expectations, including the likelihood that Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market; the Company’s ability to complete development and commercialization of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on May 16, 2016, November 12, 2015, and August 13, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 atomek@positiveidcorp.com RedChip Companies Jon Cunningham (407) 644-4256 jon@redchip.com
